Jazz Pharmaceuticals plc Cash and Cash Equivalents, Period Increase (Decrease)
Jazz Pharmaceuticals plc (JAZZ) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$76.41 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-26
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$189.40M, a 241.95% decline year-over-year.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $13.94M, a 3.99% increase year-over-year.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $31.91M.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $67.13M.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$76.41M, a 480.69% decline from fiscal 2017.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for fiscal 2017 was $20.07M.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$622.82M, a 304.38% decline from fiscal 2015.
- Jazz Pharmaceuticals plc cash and cash equivalents, period increase (decrease) for fiscal 2015 was $304.74M, a 541.05% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$189.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$175.46M derived: sum of 2 quarters · filed 2019-02-26 | -$143.55M derived: sum of 3 quarters · filed 2019-02-26 | -$76.41M 10-K · filed 2019-02-26 |
| 2018-09-30 | $13.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $45.85M derived: sum of 2 quarters · filed 2018-11-06 | $112.98M 10-Q · filed 2018-11-06 | $246.40M derived: sum of 4 quarters · filed 2019-02-26 |
| 2018-06-30 | $31.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $99.05M 10-Q · filed 2018-08-07 | $232.47M derived: sum of 3 quarters · filed 2019-02-26 | $245.87M derived: sum of 4 quarters · filed 2019-02-26 |
| 2018-03-31 | $67.13M 10-Q · filed 2018-05-08 | $200.55M derived: sum of 2 quarters · filed 2019-02-26 | $213.96M derived: sum of 3 quarters · filed 2019-02-26 | $106.17M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-12-31 | $133.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $146.82M derived: sum of 2 quarters · filed 2019-02-26 | $39.04M derived: sum of 3 quarters · filed 2019-02-26 | $20.07M 10-K · filed 2019-02-26 |
| 2017-09-30 | $13.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$94.38M derived: sum of 2 quarters · filed 2018-11-06 | -$113.35M 10-Q · filed 2018-11-06 | -$113.95M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | -$107.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$126.75M 10-Q · filed 2018-08-07 | -$127.35M derived: sum of 3 quarters · filed 2019-02-26 | -$628.75M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | -$18.97M 10-Q · filed 2018-05-08 | -$19.57M derived: sum of 2 quarters · filed 2019-02-26 | -$520.97M derived: sum of 3 quarters · filed 2019-02-26 | -$632.78M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | -$604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$502.00M derived: sum of 2 quarters · filed 2019-02-26 | -$613.82M derived: sum of 3 quarters · filed 2019-02-26 | -$622.82M 10-K · filed 2019-02-26 |
| 2016-09-30 | -$501.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$613.21M derived: sum of 2 quarters · filed 2017-11-07 | -$622.22M 10-Q · filed 2017-11-07 | -$632.29M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$111.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$120.82M 10-Q · filed 2017-08-08 | -$130.89M derived: sum of 3 quarters · filed 2018-02-27 | -$53.68M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$9.01M 10-Q · filed 2017-05-09 | -$19.08M derived: sum of 2 quarters · filed 2018-02-27 | $58.14M derived: sum of 3 quarters · filed 2018-02-27 | $197.18M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$10.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $67.14M derived: sum of 2 quarters · filed 2018-02-27 | $206.18M derived: sum of 3 quarters · filed 2018-02-27 | $304.74M 10-K · filed 2018-02-27 |
| 2015-09-30 | $77.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $216.26M derived: sum of 2 quarters · filed 2016-11-08 | $314.82M 10-Q · filed 2016-11-08 | $423.82M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $139.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $237.60M 10-Q · filed 2016-08-09 | $346.60M derived: sum of 3 quarters · filed 2017-02-28 | $653.39M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $98.56M 10-Q · filed 2016-05-10 | $207.56M derived: sum of 2 quarters · filed 2017-02-28 | $514.35M derived: sum of 3 quarters · filed 2017-02-28 | $536.73M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $415.79M derived: sum of 2 quarters · filed 2017-02-28 | $438.17M derived: sum of 3 quarters · filed 2017-02-28 | $47.54M 10-K · filed 2017-02-28 |
| 2014-09-30 | $306.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $329.17M derived: sum of 2 quarters · filed 2015-11-09 | -$61.46M 10-Q · filed 2015-11-09 | -$13.42M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-06-30 | $22.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$368.25M 10-Q · filed 2015-08-05 | -$320.21M derived: sum of 3 quarters · filed 2016-02-23 | -$236.05M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-03-31 | -$390.63M 10-Q · filed 2015-05-07 | -$342.59M derived: sum of 2 quarters · filed 2016-02-23 | -$258.43M derived: sum of 3 quarters · filed 2016-02-23 | -$204.64M derived: sum of 4 quarters · filed 2016-02-23 |
| 2013-12-31 | $48.04M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $132.20M derived: sum of 2 quarters · filed 2016-02-23 | $185.99M derived: sum of 3 quarters · filed 2016-02-23 | $249.31M 10-K · filed 2016-02-23 |
| 2013-09-30 | $84.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $137.95M derived: sum of 2 quarters · filed 2014-11-04 | $201.27M 10-Q · filed 2014-11-04 | $398.67M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $53.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $117.11M 10-Q · filed 2014-08-05 | $314.51M derived: sum of 3 quarters · filed 2015-02-24 | $349.76M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $63.31M 10-Q · filed 2014-05-08 | $260.72M derived: sum of 2 quarters · filed 2015-02-24 | $295.97M derived: sum of 3 quarters · filed 2015-02-24 | $279.86M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $197.40M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $232.65M derived: sum of 2 quarters · filed 2015-02-24 | $216.54M derived: sum of 3 quarters · filed 2015-02-24 | $305.12M 10-K · filed 2015-02-24 |
| 2012-09-30 | $35.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $19.14M derived: sum of 2 quarters · filed 2013-11-05 | $107.72M 10-Q · filed 2013-11-05 | $88.58M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$16.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $72.47M 10-Q · filed 2013-08-06 | $53.33M derived: sum of 3 quarters · filed 2014-02-25 | $52.15M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $88.58M 10-Q · filed 2013-05-07 | $69.44M derived: sum of 2 quarters · filed 2014-02-25 | $68.26M derived: sum of 3 quarters · filed 2014-02-25 | $105.59M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | -$19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$20.32M derived: sum of 2 quarters · filed 2014-02-25 | $17.02M derived: sum of 3 quarters · filed 2014-02-25 | $37.28M 10-K · filed 2014-02-25 |
| 2011-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $36.15M derived: sum of 2 quarters · filed 2012-11-09 | $56.42M 10-Q · filed 2012-11-09 | $78.36M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $37.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $57.60M 10-Q · filed 2012-08-07 | $79.54M derived: sum of 3 quarters · filed 2013-02-26 | $92.82M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $20.27M 10-Q · filed 2012-05-08 | $42.21M derived: sum of 2 quarters · filed 2013-02-26 | $55.49M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | $21.94M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $35.22M derived: sum of 2 quarters · filed 2013-02-26 | $29.20M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $13.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $7.26M 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | -$6.02M 10-Q · filed 2011-08-03 | |||
| 2009-12-31 | -$9.31M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |